INVO Fertility (IVF) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 increased 18% year-over-year to $2.2 million, driven by the addition of the Indiana Clinic and growth at existing clinics.

• Net income for Q2 2026 was $0.9 million, a significant improvement from a net loss of $3.6 million in Q2 2025, primarily due to gains from business combinations and reduced non-cash expenses.

• The company completed the acquisition of Family Beginnings (Indiana Clinic) in February 2026 and acquired full ownership of the Alabama JV in June 2026, expanding its clinic footprint to four U.S. locations.

• A warrant inducement in January 2026 raised $7.1 million, supporting acquisition payments and debt reduction.

Financial highlights

• Q2 2026 revenue: $2.2 million (up from $1.8 million in Q2 2025); six-month revenue: $4.2 million (up from $3.5 million in 2025).

• Q2 2026 net income: $0.9 million; six-month net loss: $4.7 million (improved from $21.0 million loss in 2025).

• Gross margin improved due to higher clinic revenue and lower impairment and non-cash expenses.

• Cash at June 30, 2026: $3.7 million (up from $0.5 million in 2025); stockholders' equity: $16.5 million (up from $7.2 million at year-end 2025).

Outlook and guidance

• Plans to grow clinic revenue organically and through additional profitable fertility clinic acquisitions.

• Ongoing focus on expanding the clinic network and leveraging the INVOcell device within and outside company-owned clinics.

• Substantial doubt remains about the ability to continue as a going concern without additional funding; management is actively seeking further debt and equity financing.